Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/5/2009

mercial infrastructure in preparation for the potential commercialization of Acetavance. More specifically, during the three months ended September 30, 2009, Cadence hired its sales management team for the potential launch of Acetavance, if approved, and is currently recruiting sales representatives contingent on FDA approval. Cadence also increased spending related to the development of marketing materials and programs during the three months ended September 30, 2009. In addition, general and administrative expenses increased during the current quarter primarily due to increased personnel costs, including an additional $0.6 million in stock-based compensation charges.

For the nine months ended September 30, 2009, Cadence reported a net loss of $30.2 million, or $0.63 per share, compared to a net loss of $43.1 million, or $1.18 per share, for the same period in 2008. Operating expenses for the nine months ended September 30, 2009 were $29.4 million, a decrease of $13.6 million from the $43.0 million reported for the comparable period in 2008. The decrease in current year expenses is primarily due to a reduction in research and development costs as a result of the company's discontinuation of the development program for its omiganan product candidate in March 2009, the completion of its clinical development program for Acetavance in early 2009, and the submission of its NDA for Acetavance in May 2009. Partially offsetting this reduction is an increase in sales and marketing expenses in 2009 as the company began establishing its commercial and supply operation functions in preparation for the potential commercialization of Acetavance. General and administrative expenses increased during the current year primarily due to increased personnel costs, including an additional $0.8 million in stock-based compensation charges.

As of September 30, 2009, Cadence held cash, cash equivalents and short-term investments of $96.6 million.

Confere
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
3. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
4. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
9. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... San Luis Obispo, CA (PRWEB) September 18, 2014 ... Bunion Bootie introduced their newest, patent pending bunion splint ... , As one loyalist, Rosa, wrote: "I was absolutely delighted. ... comfortable... I honestly forget I am wearing them. THANK YOU ... the recently introduced design by saying, "The hole used to ...
(Date:9/18/2014)... It is that time of year – time ... again, Evensong Spa at Heidel House Resort ... at a special $50 rate Oct. 20 through Nov. 1. ... & Resorts , is the only Wisconsin destination spa participating ... health and wellness by experiencing affordable spa and wellness treatments. ...
(Date:9/18/2014)... (HealthDay News) -- Daily supplements of selenium or vitamin ... of age-related cataracts among men, a new study indicates. ... both could help prevent cataracts. To investigate this further, ... Medical School in Boston, and his colleagues examined data ... E. The trial was initially designed to study prevention ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
(Date:9/18/2014)... Qualis Health, one of the nation’s leading population ... “Advancing Primary Care through the Patient-Centered Medical Home Model ... Jeff Hummel, MD, MPH and Peggy C. Evans, PhD, ... the work of becoming a Patient-Centered Medical Home (PCMH) ... such as generating and providing useful data that can ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
... ... Learning, is happy to announce the release of their new title in the Tarascon ... Dacso, MD, MSc. This convenient, portable guide provides regional and issue-based information on ... ...
... sense of family discord implicated in new study , ... and psychology may be the cause of attention-deficit hyperactivity disorder ... found that ADHD symptoms were more common in children and ... serotonin and who blame themselves for conflict between their parents. ...
... "We ... the easy to use workflow currently enjoyed by HyperSign subscribers and allow them to ... ... a S.C.- based technology development company announced today that its award winning digital signage ...
... the University of Alabama at Birmingham (UAB) Department of ... will help predict which patients are more likely to ... findings also shed light on the genetics that result ... Caucasians, the researchers said. In data presented April ...
... ... selling their premium brand electronic cigarettes via the internet. , ... Reno, NV (PRWEB) April 18, 2010 -- ... electronic cigarettes via the internet. Previously, Freedom was sold exclusively through retail outlets. ...
... ... fire sprinklers had been installed in these homes, many of these lives would have been saved. ... these live-safety systems in homes are well trained and accredited. , ... Whittier, CA (PRWEB) April 19, 2010 -- More than 3,000 people in ...
Cached Medicine News:Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 2Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 3Health News:Award Winning HyperSign Digital Signage Service Now Includes Interactive Signage 2Health News:UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis 2Health News:Freedom Smokeless Electronic Cigarette Sales Are Smoke ‘N 2Health News:Partnering to Enhance Consumer Safety with Residential Fire Sprinklers 2Health News:Partnering to Enhance Consumer Safety with Residential Fire Sprinklers 3
(Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics Unlimited, ... , Ph.D. to its corporate Advisory Board for ... instructor at the Harvard Medical School and Visiting ... He received his Masters degree in Electronics Engineering ... from the University of Bologna. After spending a year ...
(Date:9/18/2014)... Sept. 18, 2014  A $3 million grant from ... University of Michigan to establish a national center of ... Center for Aging Research at U-M will focus on ... slow the effects of aging and postpone diseases in ... that can help develop medications that may help people ...
(Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4
... 20, 2011 Reportlinker.com announces that a new ... Rheumatoid Arthritis Market Forecast ... launch of novel oral drugs and reformulations of ... the seven major markets, rising from $12bn in ...
... Sept. 20, 2011 Reportlinker.com announces ... is available in its catalogue: ... Therapy (HRT) - Pipeline Assessment and ... http://www.reportlinker.com/p0617091/Post-Menopausal-Hormone-Replacement-Therapy-HRT---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy ...
Cached Medicine Technology:Rheumatoid Arthritis Market Forecast 2Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 2Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 3Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 4Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 5Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 6Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 7Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 8Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 9
... Tecoflex stents that save inventory, shelf space, ... ureteral lengths from 22 cm to 28 ... Quadra-Coil to glide over any guidewire and ... provide ease of placement and patient comfort ...
... for temporary internal drainage from the ... sterile in peel-open packages. Intended for ... advised; C-Flex® and Sof-Flex® stents must ... (6) months; silicone stents must not ...
... Classic Double Pigtail Ureteral Stents have ... that maximizes migration. They also feature ... and cost savings. Each Classic ... one Classic Double PigTail Ureteral Stent ...
... internal drainage from the ureteropelvic ... filiform stent assembly provides one ... peel-open packages. Intended for one-time ... advised; stent must not remain ...
Medicine Products: